Patients with high-risk melanoma who received the anti–PD-1 therapy pembrolizumab both before and after surgery to remove cancerous tissue had a significantly lower risk of their cancer recurring than similar patients who received the drug only after surgery.
Clinical Trials
Study: Fianlimab With Cemiplimab Combination Shows High Response Rate in Certain Patients With Advanced Melanoma
New research presented at ESMO Congress found that certain patients with advanced melanoma administered a combination of cemiplimab with fianlimab experienced a median progression-free survival of 2 years.
Nivolumab Elicits Statistically Significant Improvement in RFS in Stage IIB/C Melanoma
Adjuvant nivolumab (Opdivo) monotherapy elicited a statistically significant and clinically meaningful improvement in recurrence-free survival (RFS) compared with placebo for patients with completely resected stage IIB/C melanoma, according to a press release from Bristol Myers Squibb (BMS).
Sequencing of Ipilimumab/Nivolumab With Encorafenib/Binimetinib in BRAF-Mutant Metastatic Melanoma
In a phase II trial (SECOMBIT) reported in the Journal of Clinical Oncology, Paolo A. Ascierto, MD, and colleagues found that sequential immunotherapy and targeted therapy with ipilimumab/nivolumab followed at disease progression by encorafenib/binimetinib was associated with good survival outcomes in previously untreated patients with BRAF V600–mutant metastatic melanoma.